Clinical Trials Logo

Cisplatin Adverse Reaction clinical trials

View clinical trials related to Cisplatin Adverse Reaction.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05586009 Enrolling by invitation - Clinical trials for Cisplatin Adverse Reaction

Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients

Start date: October 2022
Phase: Phase 2
Study type: Interventional

The goal of this [ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.] In 75 participant population with head and neck cancer recieved cisplatin it aims to answer are: • • optimal doses of magnesium as 3 groups each group take 1gm of magnesium then second group take 2gm of magnesium and finally third group take 3gm of magnesium Researchers will compare [ 3 groups ] to see if [ magnesium has effects in prevention cisplatin nephrotoxicity].